Cellectis S.A. - American Depositary Shares (NQ:CLLS)

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS

Performance

52-Week Range 74.6% below 52-week high

1.390

1.2552W Low 5.4852W High

1 Week 8.9% below 1-week high

1.401W Low 1.521W High

Cellectis S.A. - American Depositary Shares (CLLS) traded between $1.25 and $5.48 over the past 52 weeks and last traded at $1.39, 74.6% below its 52-week high. Over the past week it ranged between $1.40 and $1.52.

Past 12 Months

-6.1%

-57.1%

-57.8%

-59.6%

-71.0%

-60.6%

1W -$0.09

1M -$1.85

3M -$1.90

6M -$2.05

YTD -$3.41

1Y -$2.14

CLLS was -60.6% over the past year, -59.6% over six months, -71.0% year to date, -6.1% in the last week.

12 Months vs Market

CLLS

-60.6%

DIA

+9.3%

SPY

+15.0%

QQQ

+23.8%

IWM

+14.5%

Over the past 12 months CLLS returned -60.6% versus DIA (Dow) +9.3%, SPY (S&P 500) +15.0%, QQQ (Nasdaq 100) +23.8% and IWM (Russell 2000) +14.5%.

Volume & Liquidity 0.18× 3-mo avg

Today 13,740 3-mo avg 76.7K

69.3K

209.2K

76.7K

58.0K

YTD

53.7K

75.0K

CLLS most recently traded 13,740 shares against a 3-month average daily volume of 76.7K.

More News

September 22, 2026

From Pomerantz LLP

CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law

September 19, 2026

From Schall, Brown & Schwartz LLP

Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

September 17, 2026

From Glancy Prongay Wolke & Rotter LLP

Cellectis S.A. (CLLS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

September 17, 2026

From Law Offices of Howard G. Smith

Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

September 16, 2026

From The Law Offices of Frank R. Cruz

Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company

September 14, 2026

Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update

September 11, 2026

Cellectis Announces Participation in Upcoming Investor Conferences

September 01, 2026

Cellectis Reports Financial Results for the Second Quarter 2026

August 06, 2026

Cellectis to Report Second Quarter Financial Results on August 6, 2026

July 30, 2026

Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio

July 15, 2026

From ProLynx Inc.

Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026

June 25, 2026

Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress

June 11, 2026

Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL

June 09, 2026

Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline ↗

May 21, 2026

Via The Motley Fool

Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year ↗

May 21, 2026

Via The Motley Fool

Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026

May 20, 2026

Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress

May 12, 2026

Cellectis Reports Financial Results for the First Quarter 2026

May 11, 2026

Cellectis to Report First Quarter Financial Results on May 11, 2026

May 04, 2026

Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting

April 27, 2026

Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform

April 13, 2026